-
5/21/2024
Aligos Therapeutics，Inc.today announced that it has completed enrollment in the ALG-055009 Phase2a HERALD study for metabolic dysfunction-associated steatohepatititis（MASH）with topline safety and efficacy data anticipated in early Q4 2024。
-
5/21/2024
Bionano Genomics today announced the publication of three studies which collectively illustrate the continued development of data supporting the utility of optical genome mapping（OGM）in cell and gene therapy applications。
-
5/21/2024
Tonix Pharmaceuticals Holding Corp.announced today that EVERSANA®Life Science Services，LLC，aleading provider of commercialization services to the global life sciences industry，completed the initial phase of an assessment of the U.S market opportunity for TonmyaTM（also known as TNX-102 SL，cyclobenzaprine HCl sublingual tablets），a poteal new firsline firs of apliment a。
-
5/21/2024
从ADORING1and ADORING2，two identical，double-blind，randomized，vehicle-controlled pivotal Phase3trials of VTAMA®（tapinarof）cream，1%for adults and children2years of age and older with atopic dermatis（AD）has been published in the Journal of the American Academy of Dermatology。
-
5/21/2024
Indapta Therapeutics，Inc.today announced that Cancer Prevention and Research Institute of Texas（CPRIT）has granted the company a competitive product development research award。
-
5/21/2024
Alvotech and Dr.Reddy’s Laboratories today announced that the companies have entered into a license and supply agement for the commercialization of AVT03，Alvotech’s biosimilar candidate to Prolia®and Xgeva®（denosumab）。
-
5/21/2024
Edgewood Oncology today announced that the first two patients with metastatic breast cancer were treated with BTX-A51，amulti-specific kinase inhibitor of casein kinase1alpha（CK1α）and cyclin-dependent kinases7and9（CDK7and CDK9），that synergistically targets master regulators of cancer。
-
5/21/2024
Alloy Therapeutics announced today a licensing agreement for its murine platforms for fully human antibody discovery with Eli Lilly and Company。
-
5/21/2024
PureTech Health plc noted that its Founded Entity，Vedanta Biosciences announced that the first patient has been dosed in the global Phase3RESTORATiVE303clinical study of VE303，which is an orally administered defined defined bacterial consortium candidate that is being developed for the prevention of revention of rectifection。
-
5/21/2024
Vedanta Biosciences，aclinical-stage company that is developing a portential new category of oral therapies based on defined bacterial consortia，announced that the first patient has been dosed in the global Phase3RESTORATiVE303clinical study。
-
5/21/2024
Palisade Bio，Inc.today announced the presentation of positive preclinical data from PALI-2108，an orally administered，locally acting colon-specific Phosphodiesterase-4（PDE4）inhibitor prodrug in development for patients affected by UC，at DDW2024being held in Washington，D.C.2024，Matients affeced by。
-
5/21/2024
GRI Bio，Inc.today announced Vipin Kumar Chaturvedi，PhD，Chief Scientific Officer of GRI Bio presented encouraging preclinical data from the Company’s preclinical studies of type2NKT activating molecules，GRI-0803and GRI-0124 at the 14th International Congresson Automunivating moleculd jana，Slovenia（the Congress）。
-
5/21/2024
Molecure S.A.announces today that it has received national regulatory approvals from Denmark，France，Greece，Germany and Norway to conduct a Phase II clinical trial for OAtD-01，afirst-in-class chitotriosidase1（CHIT1）inhibitor with disease-modifying poteal in pullonsarcois。
-
5/21/2024
Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase1/2 Clinical Study of Q901 in Combination with TROP2-ADC。
-
5/21/2024
Ironwood Pharmaceuticals，Inc.will present late-breaking data during the 2024 Digestive Disease Week®meeting from its pivotal Phase III clinical trial，STARS，which evaluated the efficy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure。
-
5/21/2024
CorDx announced a transformative$21M gift to the University of California San Diego’s Jacobs School of Engineering from CorDx founder Aiiso Yufeng Li，with support from members of the CorDx family-Li’s wife，Aiiso DongDong Li，Mac Chen，Haixia Yang，Monica Hut，Colot and Corot。
-
5/21/2024
Sana Biotechnology，Inc.today high lighted that Nature Biotechnology has published a paper titled“Young glial progenitor cells competitively replace aged and diseased human glia in the adult chimeric mouse brain.”
-
5/21/2024
Cali Biosciences Co.，Ltd.announced publication of“CPL‑01，an investigational long‑acting ropivacaine，demonstrates safety and efficy in open inguinal hernia repair”in the scientific journal Hernia。
-
5/21/2024
Deep Blue Medical Advances announced today it has received the Luis Villalobos Award–Life Sciences from the Angel Capital Association（ACA），a professional association of more than15000 accredited angel investors and 250 angel groups，accredited platforms and family offices across North America。
-
5/21/2024
PharmaCyte Biotech，Inc.today announced a$7million investment in MyMD Pharmaceuticals，Inc。
